Annual CFO
-$95.14 M
+$66.71 M+41.22%
31 December 2023
Summary:
BioCryst Pharmaceuticals annual cash flow from operations is currently -$95.14 million, with the most recent change of +$66.71 million (+41.22%) on 31 December 2023. During the last 3 years, it has risen by +$39.97 million (+29.58%). BCRX annual CFO is now -2894.12% below its all-time high of -$3.18 million, reached on 31 December 2000.BCRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$8.24 M
+$9.61 M+702.70%
30 September 2024
Summary:
BioCryst Pharmaceuticals quarterly cash flow from operations is currently $8.24 million, with the most recent change of +$9.61 million (+702.70%) on 30 September 2024. Over the past year, it has increased by +$28.14 million (+141.44%). BCRX quarterly CFO is now -68.71% below its all-time high of $26.35 million, reached on 31 March 2006.BCRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$55.73 M
+$28.14 M+33.56%
30 September 2024
Summary:
BioCryst Pharmaceuticals TTM cash flow from operations is currently -$55.73 million, with the most recent change of +$28.14 million (+33.56%) on 30 September 2024. Over the past year, it has increased by +$54.35 million (+49.37%). BCRX TTM CFO is now -752.69% below its all-time high of $8.54 million, reached on 31 March 2006.BCRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +41.2% | +141.4% | +49.4% |
| 3 y3 years | +29.6% | +135.4% | +63.4% |
| 5 y5 years | -2.8% | +129.8% | +46.0% |
BCRX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +41.2% | at high | +110.6% | at high | +67.3% |
| 5 y | 5 years | -6.2% | +41.2% | at high | +110.6% | at high | +67.8% |
| alltime | all time | -2894.1% | +41.2% | -68.7% | +110.6% | -752.7% | +67.8% |
BioCryst Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $8.24 M(-702.7%) | -$55.73 M(-33.6%) |
| June 2024 | - | -$1.37 M(-97.5%) | -$83.87 M(-17.2%) |
| Mar 2024 | - | -$53.68 M(+502.0%) | -$101.31 M(+6.5%) |
| Dec 2023 | -$95.14 M(-41.2%) | -$8.92 M(-55.2%) | -$95.14 M(-13.6%) |
| Sept 2023 | - | -$19.90 M(+5.8%) | -$110.07 M(-10.2%) |
| June 2023 | - | -$18.81 M(-60.4%) | -$122.62 M(-6.8%) |
| Mar 2023 | - | -$47.51 M(+99.2%) | -$131.56 M(-18.7%) |
| Dec 2022 | -$161.85 M(+13.9%) | -$23.85 M(-26.5%) | -$161.85 M(-5.1%) |
| Sept 2022 | - | -$32.44 M(+16.9%) | -$170.46 M(+5.7%) |
| June 2022 | - | -$27.76 M(-64.3%) | -$161.29 M(+1.5%) |
| Mar 2022 | - | -$77.80 M(+139.7%) | -$158.95 M(+11.8%) |
| Dec 2021 | -$142.16 M(+5.2%) | -$32.46 M(+39.5%) | -$142.16 M(-6.6%) |
| Sept 2021 | - | -$23.28 M(-8.4%) | -$152.23 M(-9.0%) |
| June 2021 | - | -$25.41 M(-58.4%) | -$167.21 M(-3.3%) |
| Mar 2021 | - | -$61.01 M(+43.5%) | -$172.84 M(+27.9%) |
| Dec 2020 | -$135.11 M(+50.8%) | -$42.53 M(+11.2%) | -$135.11 M(+31.1%) |
| Sept 2020 | - | -$38.26 M(+23.2%) | -$103.03 M(+11.5%) |
| June 2020 | - | -$31.04 M(+33.3%) | -$92.41 M(+7.6%) |
| Mar 2020 | - | -$23.28 M(+122.8%) | -$85.87 M(-4.1%) |
| Dec 2019 | -$89.58 M(-3.2%) | -$10.45 M(-62.2%) | -$89.58 M(-13.1%) |
| Sept 2019 | - | -$27.64 M(+12.8%) | -$103.12 M(-6.7%) |
| June 2019 | - | -$24.50 M(-9.2%) | -$110.52 M(+10.6%) |
| Mar 2019 | - | -$27.00 M(+12.6%) | -$99.91 M(+7.9%) |
| Dec 2018 | -$92.56 M(+125.0%) | -$23.98 M(-31.5%) | -$92.56 M(+17.0%) |
| Sept 2018 | - | -$35.03 M(+152.1%) | -$79.10 M(+40.0%) |
| June 2018 | - | -$13.89 M(-29.3%) | -$56.50 M(+8.1%) |
| Mar 2018 | - | -$19.65 M(+86.8%) | -$52.27 M(+27.0%) |
| Dec 2017 | -$41.14 M(-23.0%) | -$10.52 M(-15.4%) | -$41.14 M(+12.8%) |
| Sept 2017 | - | -$12.43 M(+28.6%) | -$36.48 M(-12.3%) |
| June 2017 | - | -$9.67 M(+13.4%) | -$41.61 M(-3.5%) |
| Mar 2017 | - | -$8.53 M(+45.7%) | -$43.12 M(-19.3%) |
| Dec 2016 | -$53.44 M(+307.4%) | -$5.85 M(-66.7%) | -$53.44 M(-14.4%) |
| Sept 2016 | - | -$17.56 M(+57.0%) | -$62.41 M(+8.5%) |
| June 2016 | - | -$11.18 M(-40.6%) | -$57.51 M(+103.7%) |
| Mar 2016 | - | -$18.84 M(+27.1%) | -$28.23 M(+115.2%) |
| Dec 2015 | -$13.12 M(-66.0%) | -$14.83 M(+17.1%) | -$13.12 M(+7.7%) |
| Sept 2015 | - | -$12.66 M(-170.0%) | -$12.18 M(+50.0%) |
| June 2015 | - | $18.10 M(-585.7%) | -$8.12 M(-75.6%) |
| Mar 2015 | - | -$3.73 M(-73.2%) | -$33.32 M(-13.6%) |
| Dec 2014 | -$38.55 M(+45.3%) | -$13.89 M(+61.5%) | -$38.55 M(+32.1%) |
| Sept 2014 | - | -$8.60 M(+21.1%) | -$29.18 M(+2.4%) |
| June 2014 | - | -$7.10 M(-20.7%) | -$28.50 M(+17.3%) |
| Mar 2014 | - | -$8.96 M(+98.4%) | -$24.29 M(-8.4%) |
| Dec 2013 | -$26.53 M(-29.1%) | -$4.51 M(-43.0%) | -$26.53 M(-8.7%) |
| Sept 2013 | - | -$7.92 M(+173.6%) | -$29.05 M(-11.7%) |
| June 2013 | - | -$2.90 M(-74.1%) | -$32.90 M(-9.5%) |
| Mar 2013 | - | -$11.20 M(+59.3%) | -$36.35 M(-2.8%) |
| Dec 2012 | -$37.40 M(+16.0%) | -$7.03 M(-40.3%) | -$37.40 M(+8.9%) |
| Sept 2012 | - | -$11.78 M(+85.7%) | -$34.35 M(+4.0%) |
| June 2012 | - | -$6.34 M(-48.2%) | -$33.04 M(+9.5%) |
| Mar 2012 | - | -$12.25 M(+207.4%) | -$30.17 M(-6.4%) |
| Dec 2011 | -$32.25 M(+12.9%) | -$3.98 M(-61.9%) | -$32.25 M(-5.4%) |
| Sept 2011 | - | -$10.47 M(+201.6%) | -$34.09 M(+3.8%) |
| June 2011 | - | -$3.47 M(-75.8%) | -$32.85 M(-12.9%) |
| Mar 2011 | - | -$14.33 M(+146.2%) | -$37.69 M(+32.0%) |
| Dec 2010 | -$28.55 M(+76.1%) | -$5.82 M(-36.9%) | -$28.55 M(+118.0%) |
| Sept 2010 | - | -$9.23 M(+10.9%) | -$13.10 M(+45.6%) |
| June 2010 | - | -$8.32 M(+60.4%) | -$9.00 M(-27.1%) |
| Mar 2010 | - | -$5.19 M(-153.8%) | -$12.35 M(-23.9%) |
| Dec 2009 | -$16.22 M | $9.64 M(-288.0%) | -$16.22 M(-46.6%) |
| Sept 2009 | - | -$5.13 M(-56.1%) | -$30.39 M(-2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$11.67 M(+28.8%) | -$31.19 M(+22.6%) |
| Mar 2009 | - | -$9.06 M(+99.7%) | -$25.43 M(+21.8%) |
| Dec 2008 | -$20.87 M(-16.5%) | -$4.54 M(-23.3%) | -$20.87 M(-35.5%) |
| Sept 2008 | - | -$5.92 M(+0.1%) | -$32.34 M(+3.8%) |
| June 2008 | - | -$5.92 M(+31.4%) | -$31.16 M(+19.4%) |
| Mar 2008 | - | -$4.50 M(-71.9%) | -$26.10 M(+4.4%) |
| Dec 2007 | -$25.00 M(+64.3%) | -$16.00 M(+237.6%) | -$25.00 M(+4.7%) |
| Sept 2007 | - | -$4.74 M(+454.5%) | -$23.87 M(-25.7%) |
| June 2007 | - | -$855.00 K(-74.8%) | -$32.14 M(-28.5%) |
| Mar 2007 | - | -$3.40 M(-77.2%) | -$44.96 M(+195.5%) |
| Dec 2006 | -$15.21 M(-34.8%) | -$14.88 M(+14.3%) | -$15.21 M(+149.8%) |
| Sept 2006 | - | -$13.01 M(-4.8%) | -$6.09 M(-878.7%) |
| June 2006 | - | -$13.67 M(-151.9%) | $781.80 K(-90.8%) |
| Mar 2006 | - | $26.35 M(-558.0%) | $8.54 M(-136.6%) |
| Dec 2005 | -$23.35 M(+28.6%) | -$5.75 M(-6.3%) | -$23.35 M(+1.5%) |
| Sept 2005 | - | -$6.14 M(+3.8%) | -$23.01 M(+11.0%) |
| June 2005 | - | -$5.92 M(+6.8%) | -$20.73 M(+6.5%) |
| Mar 2005 | - | -$5.54 M(+2.2%) | -$19.47 M(+7.3%) |
| Dec 2004 | -$18.15 M(+62.1%) | -$5.42 M(+40.2%) | -$18.15 M(+17.6%) |
| Sept 2004 | - | -$3.86 M(-16.9%) | -$15.44 M(+5.7%) |
| June 2004 | - | -$4.65 M(+10.3%) | -$14.61 M(+14.5%) |
| Mar 2004 | - | -$4.22 M(+55.9%) | -$12.76 M(+14.0%) |
| Dec 2003 | -$11.20 M(-31.6%) | -$2.71 M(-10.6%) | -$11.20 M(+4.2%) |
| Sept 2003 | - | -$3.03 M(+8.0%) | -$10.74 M(-3.0%) |
| June 2003 | - | -$2.81 M(+5.6%) | -$11.08 M(-14.7%) |
| Mar 2003 | - | -$2.66 M(+18.1%) | -$12.98 M(-20.7%) |
| Dec 2002 | -$16.36 M(+61.1%) | -$2.25 M(-33.1%) | -$16.36 M(-5.9%) |
| Sept 2002 | - | -$3.36 M(-28.6%) | -$17.39 M(+7.3%) |
| June 2002 | - | -$4.71 M(-22.0%) | -$16.21 M(+16.1%) |
| Mar 2002 | - | -$6.04 M(+84.1%) | -$13.97 M(+37.5%) |
| Dec 2001 | -$10.16 M(+219.7%) | -$3.28 M(+50.3%) | -$10.16 M(+17.3%) |
| Sept 2001 | - | -$2.18 M(-11.4%) | -$8.66 M(+0.5%) |
| June 2001 | - | -$2.46 M(+10.4%) | -$8.61 M(+11.4%) |
| Mar 2001 | - | -$2.23 M(+25.4%) | -$7.74 M(+143.4%) |
| Dec 2000 | -$3.18 M(-35.2%) | -$1.78 M(-16.8%) | -$3.18 M(+87.1%) |
| Sept 2000 | - | -$2.14 M(+35.0%) | -$1.70 M(+2.4%) |
| June 2000 | - | -$1.58 M(-168.1%) | -$1.66 M(-6240.7%) |
| Mar 2000 | - | $2.33 M(-875.7%) | $27.00 K(-100.6%) |
| Dec 1999 | -$4.90 M(+16.7%) | -$300.00 K(-85.7%) | -$4.90 M(+880.0%) |
| Sept 1999 | - | -$2.10 M(-2200.0%) | -$500.00 K(-58.3%) |
| June 1999 | - | $100.00 K(-103.8%) | -$1.20 M(-71.4%) |
| Mar 1999 | - | -$2.60 M(-163.4%) | -$4.20 M(0.0%) |
| Dec 1998 | -$4.20 M(-59.2%) | $4.10 M(-246.4%) | -$4.20 M(-62.8%) |
| Sept 1998 | - | -$2.80 M(-3.4%) | -$11.30 M(+2.7%) |
| June 1998 | - | -$2.90 M(+11.5%) | -$11.00 M(+13.4%) |
| Mar 1998 | - | -$2.60 M(-13.3%) | -$9.70 M(-5.8%) |
| Dec 1997 | -$10.30 M(+51.5%) | -$3.00 M(+20.0%) | -$10.30 M(+15.7%) |
| Sept 1997 | - | -$2.50 M(+56.3%) | -$8.90 M(+2.3%) |
| June 1997 | - | -$1.60 M(-50.0%) | -$8.70 M(+8.8%) |
| Mar 1997 | - | -$3.20 M(+100.0%) | -$8.00 M(+17.6%) |
| Dec 1996 | -$6.80 M(-11.7%) | -$1.60 M(-30.4%) | -$6.80 M(0.0%) |
| Sept 1996 | - | -$2.30 M(+155.6%) | -$6.80 M(+7.9%) |
| June 1996 | - | -$900.00 K(-55.0%) | -$6.30 M(-4.5%) |
| Mar 1996 | - | -$2.00 M(+25.0%) | -$6.60 M(-14.3%) |
| Dec 1995 | -$7.70 M(+18.5%) | -$1.60 M(-11.1%) | -$7.70 M(+1.3%) |
| Sept 1995 | - | -$1.80 M(+50.0%) | -$7.60 M(-1.3%) |
| June 1995 | - | -$1.20 M(-61.3%) | -$7.70 M(-2.5%) |
| Mar 1995 | - | -$3.10 M(+106.7%) | -$7.90 M(+21.5%) |
| Dec 1994 | -$6.50 M | -$1.50 M(-21.1%) | -$6.50 M(+30.0%) |
| Sept 1994 | - | -$1.90 M(+35.7%) | -$5.00 M(+61.3%) |
| June 1994 | - | -$1.40 M(-17.6%) | -$3.10 M(+82.4%) |
| Mar 1994 | - | -$1.70 M | -$1.70 M |
FAQ
- What is BioCryst Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual CFO year-on-year change?
- What is BioCryst Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly CFO year-on-year change?
- What is BioCryst Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals TTM CFO year-on-year change?
What is BioCryst Pharmaceuticals annual cash flow from operations?
The current annual CFO of BCRX is -$95.14 M
What is the all time high annual CFO for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual cash flow from operations is -$3.18 M
What is BioCryst Pharmaceuticals annual CFO year-on-year change?
Over the past year, BCRX annual cash flow from operations has changed by +$66.71 M (+41.22%)
What is BioCryst Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of BCRX is $8.24 M
What is the all time high quarterly CFO for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly cash flow from operations is $26.35 M
What is BioCryst Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, BCRX quarterly cash flow from operations has changed by +$28.14 M (+141.44%)
What is BioCryst Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of BCRX is -$55.73 M
What is the all time high TTM CFO for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high TTM cash flow from operations is $8.54 M
What is BioCryst Pharmaceuticals TTM CFO year-on-year change?
Over the past year, BCRX TTM cash flow from operations has changed by +$54.35 M (+49.37%)